Pentoxifylline Role Against Chemotherapy-induced Neuropathy

Inclusion Criteria: * Adult patients\> 18 years old. * Female patients Breast cancer patients who received paclitaxel-based regimen for 12 weeks. * Eastern Cooperative Oncology Group (ECOG) performance ≤ 2-Adequate bone marrow function. * Adequate liver and kidney function. Exclusion Criteria: * Children less than 18 years old. * Evidence of physical diseases or major surgery. * Patientswith a history of chronic diseases including; renal, hepatic, gastrointestinal, respiratory, hematological, and metabolic or other diseases. * Patients with preexisting clinical neuropathy. * Patients with diabetes mellitus. * Metastatic breast cancer. * Patients receiving medications that ameliorate neuropathy like; antidepressants, anticonvulsants, opioids, adjuvant or topical analgesics. * Patients treated with medications that increase the risk of neuropathy. * Hypersensitivity to pentoxifylline or xanthine derivatives. * Patients retinal bleeding or active peptic ulcer. * Patients at high risk for bleeding or taking medications that increase risk of bleeding.